Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

Young JS, Dayani F, Morshed RA, Okada H, Aghi MK.

World Neurosurg. 2019 Jan 21. pii: S1878-8750(19)30106-8. doi: 10.1016/j.wneu.2018.12.222. [Epub ahead of print] Review.

PMID:
30677574
2.

Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors.

Sahebjam S, Stallworth DG, Mokhtari S, Tran ND, Arrington JA.

Cancer Control. 2017 Apr;24(2):180-186.

PMID:
28441372
3.

The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses.

Maxwell R, Luksik AS, Garzon-Muvdi T, Lim M.

Curr Neurol Neurosci Rep. 2017 Jun;17(6):50. doi: 10.1007/s11910-017-0754-x. Review.

PMID:
28488122
4.

Single vs. combination immunotherapeutic strategies for glioma.

Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav VN, Koschmann C, Asad AS, Lowenstein PR, Castro MG.

Expert Opin Biol Ther. 2017 May;17(5):543-554. doi: 10.1080/14712598.2017.1305353. Epub 2017 Mar 20. Review.

5.

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.

Chen R, Cohen AL, Colman H.

Curr Treat Options Oncol. 2016 Aug;17(8):42. doi: 10.1007/s11864-016-0418-0. Review.

PMID:
27334978
6.

New Approaches for Immune Directed Treatment for Ovarian Cancer.

Hardwick N, Frankel PH, Cristea M.

Curr Treat Options Oncol. 2016 Mar;17(3):14. doi: 10.1007/s11864-016-0389-1. Review.

PMID:
26942589
7.

Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.

Ă–zdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.

Eur Urol Focus. 2018 Apr;4(3):442-454. doi: 10.1016/j.euf.2017.10.001. Epub 2017 Oct 19.

PMID:
29056275
8.

Dendritic cell immunotherapy for malignant gliomas.

Luptrawan A, Liu G, Yu JS.

Rev Recent Clin Trials. 2008 Jan;3(1):10-21. Review.

PMID:
18474011
9.

Systemic treatments for metastatic cutaneous melanoma.

Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S.

Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123. doi: 10.1002/14651858.CD011123.pub2. Review.

PMID:
29405038
10.

Advances in immunotherapeutic research for glioma therapy.

Miyauchi JT, Tsirka SE.

J Neurol. 2018 Apr;265(4):741-756. doi: 10.1007/s00415-017-8695-5. Epub 2017 Dec 5. Review.

PMID:
29209782
11.

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.

Maxwell R, Jackson CM, Lim M.

Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y. Review.

PMID:
28785997
12.

Immunotherapy approaches in the treatment of malignant brain tumors.

Dunn-Pirio AM, Vlahovic G.

Cancer. 2017 Mar 1;123(5):734-750. doi: 10.1002/cncr.30371. Epub 2016 Nov 22. Review.

13.

Immunotherapy for brain cancer: recent progress and future promise.

Jackson CM, Lim M, Drake CG.

Clin Cancer Res. 2014 Jul 15;20(14):3651-9. doi: 10.1158/1078-0432.CCR-13-2057. Epub 2014 Apr 25. Review.

14.

Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma.

Rajani KR, Carlstrom LP, Parney IF, Johnson AJ, Warrington AE, Burns TC.

Front Oncol. 2019 Feb 22;8:656. doi: 10.3389/fonc.2018.00656. eCollection 2018. Review.

15.

Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.

Ishikawa E, Yamamoto T, Matsumura A.

Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):321-330. doi: 10.2176/nmc.nmc.ra.2016-0334. Epub 2017 May 24. Review.

16.

Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top".

Simonelli M, Persico P, Perrino M, Zucali PA, Navarria P, Pessina F, Scorsetti M, Bello L, Santoro A.

Cancer Treat Rev. 2018 Sep;69:121-131. doi: 10.1016/j.ctrv.2018.06.016. Epub 2018 Jun 21. Review.

PMID:
29966936
17.

Cellular immunotherapy for malignant gliomas.

Lin Y, Okada H.

Expert Opin Biol Ther. 2016 Oct;16(10):1265-75. doi: 10.1080/14712598.2016.1214266. Epub 2016 Jul 29. Review.

18.

Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy.

Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H.

Ann Gastroenterol Surg. 2018 Jun 22;2(4):289-303. doi: 10.1002/ags3.12180. eCollection 2018 Jul. Review.

19.

Immune Checkpoint Inhibitors in Gliomas.

Tan AC, Heimberger AB, Khasraw M.

Curr Oncol Rep. 2017 Apr;19(4):23. doi: 10.1007/s11912-017-0586-5. Review.

PMID:
28303490
20.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

Supplemental Content

Support Center